Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
25.00    0.00 (0.00%)
Bid:
24.00
Ask:
26.00
Spread: 2.00 (8.333%)
Market Cap: £27.00m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Trading Update

15 Feb 2024 07:00

RNS Number : 1219D
Checkit PLC
15 February 2024
 

15 February 2024

 

Checkit plc

("Checkit" or the "Group)

 

FY24 Trading Update

 

Checkit (AIM: CKT), the intelligent operations platform for the deskless worker, announces its unaudited trading update for the year ended 31 January 2024 ("FY24").

 

· Annual recurring revenue ("ARR"1) growth of 16% to £13.3m, in line with expectations

· Focus on path to profitability is anticipated to result in better than expected losses ("LBITDA"2) halving year-on-year to £3.4m

· Recurring revenues provide good visibility for future periods underpinned by a high net revenue retention3 of 111%

 

(£'m) Reported

Twelve months to

 

31 January 2024

31 January 2023

% Change

ARR

13.3

11.5

16%

 

 

 

 

Revenue

 

 

 

Recurring

11.2

9.6

+17 %

Non-recurring

0.8

0.7

+18 %

Total Group

12.0

10.3

+17 %

 

 

 

 

 

Kit Kyte, CEO of Checkit, commented: "The second half of the year has seen further progress on our stated strategy and our drive towards profitability. Our new AI enhanced products are, we believe, best in class and a step change ahead of what's currently available in the market. We will continue to focus on driving top-line growth in the business and look forward to FY25 with confidence."

 

Results

 

Revenue has grown by 17% to £12.0m, in line with market expectations despite the challenging global economy. Our 'Land and Expand' strategy of up-selling and cross-selling has generated growth from our existing customer base, whilst at the same time we have actively identified areas of expansion and opportunity both geographically and vertically. With recurring revenues now representing 93% of the total and our high net revenue retention of 111%, we have a sound base to pursue our drive towards profitability.

 

Our focus on gross margin expansion continues to deliver and we expect losses (adjusted LBITDA) to be better than expected and nearly halve for the year to £3.4m (2023: LBITDA of £6.4m) as we drive operational efficiencies and carefully manage costs across the business.

 

Our cash position at the end of year was £9.0m (31 July 2023: £12.8m), reflecting the 46% reduction in LBITDA and the strategic purchase of inventory to mitigate supply chain constraints in the market. We expect this position to unwind over the next 12-18 months, supporting further revenue growth.

 

Product Update

 

During the year, utilising the data we collect and new AI and ML tools, we have successfully added new functionality to our products that will allow our customers to deliver sustainability and energy saving initiatives and benefit from predictive maintenance of their assets. This is being actively trialled by one of our largest customers and we are confident that these developments will provide significant value to the Group and our customers.

 

We have continued to invest in our products and our markets and we are gaining traction geographically, with 26% of ARR now generated in the US, and as we develop our offerings to address new sectors, such as food manufacturing and R&D laboratories.

 

We will provide further detail on our product strategy and the path to profitability at the time of our FY24 Results announcement in April 2024.

 

The Group's management team will host a live webinar which will include an opportunity for questions at 14:00 (GMT) today. The webinar can be accessed via the news area of the website at https://www.checkit.net/news/ or by using this link:

https://www.investormeetcompany.com/checkit-plc/register-investor

 

NOTES

 

1. Annual Recurring Revenue ("ARR") is defined as the annualised value of contracted recurring revenue from subscription services as at the period end, including committed annual recurring revenue from new wins.

2. Adjusted LBITDA is the loss on operating activities before depreciation and amortisation, share based payment charges and non-recurring or special items. Analysts' Adjusted LBITDA expectations for FY24 were £3.6m.

3. Net revenue retention is defined as the amount of recurring revenue from existing customers retained over the period, excluding new wins in the last year.

 

 

For further information, please visit www.checkit.net or contact:

 

Checkit plc

Kit Kyte (Chief Executive Officer)

Greg Price (Chief Financial and Operations Officer)

+44 (0) 1223 643313

Singer Capital Markets (Nominated Adviser & Broker)

Shaun Dobson / Harry Gooden / James Fischer

+44 (0) 20 7496 3000

Tavistock (Financial PR)

Lulu Bridges / Katie Hopkins / Simon Hudson

+44 (0) 20 7920 3150

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGCGDDXUBDGSS
Date   Source Headline
8th Apr 20269:54 amRNSForm 8.5 (EPT/RI)
7th Apr 202611:44 amRNSForm 8.3 - Checkit plc
7th Apr 202610:30 amRNSForm 8.5 (EPT/RI)
1st Apr 202610:37 amRNSForm 8.5 (EPT/RI)
1st Apr 20269:38 amRNSForm 8.3 - Checkit PLC
1st Apr 20267:47 amRNSForm 8 (OPD) - Checkit plc
31st Mar 20262:50 pmEQSForm 8.3 - Checkit PLC
31st Mar 202611:29 amRNSForm 8.3 - Checkit plc
31st Mar 202611:12 amRNSHolding(s) in Company
31st Mar 202610:51 amRNSForm 8.5 (EPT/RI)
30th Mar 20261:58 pmRNSForm 8.3 - Checkit plc
30th Mar 202610:14 amRNSForm 8.5 (EPT/RI)
27th Mar 20263:39 pmRNSForm 8.3 Check it
27th Mar 20262:43 pmRNSForm 8.3 - Checkit PLC
27th Mar 202611:44 amRNSForm 8.3 - Checkit plc
27th Mar 202611:36 amEQSForm 8.3 - Checkit PLC
27th Mar 202610:40 amRNSForm 8.5 (EPT/RI)
27th Mar 202610:32 amRNSCheckit Plc - Form 8.3
26th Mar 202610:26 amRNSForm 8.3 - Checkit PLC
26th Mar 20267:45 amRNSDisclosure Table
26th Mar 20267:00 amRNSCommencement of Formal Sale Process
19th Feb 20267:00 amRNSFY26 Trading Update
21st Jan 202611:34 amRNSHolding(s) in Company
23rd Dec 20257:00 amRNSDirector/PDMR Shareholding
23rd Dec 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20257:00 amRNSDirector/PDMR Shareholding
28th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20257:00 amRNSDirector/PDMR Shareholding
4th Nov 20257:00 amRNSDirector/PDMR Shareholding
30th Oct 20251:00 pmRNSDirector/PDMR Shareholding
28th Oct 20257:00 amRNSDirector/PDMR Shareholding
13th Oct 20252:52 pmRNSGrant of options and PDMR dealing
25th Sep 20257:00 amRNSDirector/PDMR Shareholding
26th Aug 20257:00 amRNSInterim Results
19th Jun 20252:36 pmRNSGrant of Options
5th Jun 20253:11 pmRNSResult of AGM
29th May 20257:00 amRNSPosting of Annual Report and Notice of AGM
22nd May 20257:00 amRNSDirector/PDMR Shareholding
24th Apr 20257:00 amRNSFinal Results
17th Apr 20257:00 amRNSNotice of Results and Investor Presentation
8th Apr 20257:00 amRNSStrategic update
20th Mar 202512:31 pmRNSForm 8.5 (EPT/RI) - Amendment
20th Mar 202510:21 amRNSForm 8.5 (EPT/RI)
19th Mar 202512:02 pmRNSResult of General Meeting
18th Mar 20259:43 amRNSForm 8.5 (EPT/RI)
18th Mar 20259:23 amRNSForm 8.5 (EPT/NON-RI)
17th Mar 202512:01 pmRNSForm 8.5 (EPT/RI)
17th Mar 20258:56 amRNSForm 8.5 (EPT/NON-RI)
14th Mar 202511:57 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.